Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTUS study of once-daily versus twice-daily oral mesalazine in active ulcerative colitis
NL-OMON32538Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Remission at week 8. Started Feb 2009; status: active, not recruiting.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON32538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32538.